Overview

Clinical Study of PD-1 Antibody (BGB-A317) Plus Chemotherapy (Cisplatin and Etoposide) for Limited Stage Small Cell Lung Cancer

Status:
Not yet recruiting

Trial end date:
2025-11-30

Target enrollment:

Participant gender:

Summary

This is a phase II, non-randomized, open-label, single center study to evaluate the efficacy and safety of neoadjuvant BGB-A317 + chemotherapy (cisplatin and etoposide) followed by radical surgery and adjuvant BGB-A317 immunotherapy as first-line treatment in patients limited-stage SCLC.

Phase:

Phase 2

Details

Lead Sponsor:

Shanghai Pulmonary Hospital, Shanghai, China

Treatments:

Etoposide